Key Takeaways
Stifel cut its Credo Technology price target to $250 from $310 on Nov. 20 but kept its Buy rating, and the new target is 150% above Friday’s close.
Credo is 67% below its June high as Marvell Technology buys Lumentum and MaxLinear goes after Credo’s cable business.
Astera Labs’ 154% third-quarter revenue growth says AI connectivity demand is holding up, so the question is Credo’s share and optics ramp.
At $250, Credo would trade at about 26x fiscal 2028 estimates, against 10x on Friday, so the multiple has to recover, not just the estimates.
Credo Technology (CRDO:NASDAQ) fell 15.2% to $99.86 on Friday, Nov. 20, as chip stocks sold off, leaving it 67% below its June high. The same day, Stifel cut its price target for the second time in seven weeks, to $250 from $310. It kept its Buy rating, and $250 is still 150% above the stock.
Marvell Technology (MRVL:NASDAQ) is buying Lumentum to build a bigger optics rival, while Astera Labs (ALAB:NASDAQ) just grew third-quarter revenue 154%a sign AI connectivity demand hasn’t gone anywhere.
Rivals Moved In as Credo’s Bar Went Up
Credo’s Sept. 1 report beat its own guidance, with revenue of $479.0 million, up 115% from a year earlier. But if the second quarter lands at its guidance midpoint, management’s call for more than 85% growth this fiscal year needs over $1.46 billion in the second half, and optics has to carry much of it.
On Oct. 22, MaxLinear’s CEO put Credo’s share of active electrical cables at “93% or maybe 99%,” and said MaxLinear sees 20% to 30% of the 1.6T cable market within a couple of years, selling chips to cable makers for one or two large U.S. data centers. On Nov. 2, Marvell agreed to buy Lumentum in an all-stock deal.
How Stifel Gets to $250
Stifel analyst Tore Svanberg expects a “beat and raise” on Dec. 1, on cable strength and optics execution, according to TheFly. The firm tied the cut to multiple compression across the chip industry.
Here’s our math: $250 is 26x the $9.71 of normalized EPS analysts expect in fiscal 2028, up from $9.08 90 days ago. The stock trades at 10x that same number today.
Does $250 Add Up?
The Street’s average target has climbed over the past year, from $163 to $277.
TD Cowen’s $175, cut from $300 on Nov. 16 with its Buy kept, matches the Street’s lowest target.
At about 14x the $7.30 analysts expect over the next 12 months, Credo trades below its Nov. 5 low of 15x, against a 3-year average of 61x.
If Credo’s quarterly earnings keep growing, $250 a year from now would be under 26x forward earnings. That’s below where Credo traded on Sept. 30 (27x), and below Astera Labs’ 31x on Nov. 19.
Source: finance.yahoo.com



